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Reduced hemodialysis-induced oxidative stress in end-stage re-
nal disease patients by electrolyzed reduced water.
Background. Increased oxidative stress in end-stage renal
disease (ESRD) patients may oxidize macromolecules and con-
sequently lead to cardiovascular events during chronic hemodi-
alysis. Electrolyzed reduced water (ERW) with reactive oxygen
species (ROS) scavenging ability may have a potential effect
on reduction of hemodialysis-induced oxidative stress in ESRD
patients.
Methods. We developed a chemiluminescence emission spec-
trum and high-performance liquid chromatography analysis to
assess the effect of ERW replacement on plasma ROS (H2O2
and HOCl) scavenging activity and oxidized lipid or protein
production in ESRD patients undergoing hemodialysis. Oxidized
markers, dityrosine, methylguanidine, and phosphatidylcholine
hydroperoxide, and inflammatory markers, interleukin 6 (IL-6),
and C-reactive protein (CRP) were determined.
Results. Although hemodialysis efficiently removes dityro-
sine and creatinine, hemodialysis increased oxidative stress,
including phosphatidylcholine hydroperoxide, and methylgua-
nidine. Hemodialysis reduced the plasma ROS scavenging activ-
ity, as shown by the augmented reference H2O2 and HOCl counts
(Rh2o2 and Rhocl, respectively) and decreased antioxidative
activity (expressed as total antioxidant status in this study). ERW
administration diminished hemodialyis-enhanced Rh2o2 and
Rhocl, minimized oxidized and inflammatory markers (CRP
and IL-6), and partly restored total antioxidant status during
1-month treatment.
Conclusion. This study demonstrates that hemodialysis with
ERW administration may efficiently increase the H2O2- and
HOCl-dependent antioxidant defense and reduce H2O2- and
HOCl-induced oxidative stress.
Hemodialysis is often used for removal of excessive
toxins, metabolic products, and blood components from
patients with end-stage renal diseases (ESRD). However,
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dialysis itself may further contribute to atherosclerosis by
oxidative stress, cytokine stimulation, and other events
inherent to hemodialysis [1–4]. The extracorporeal treat-
ment per se is associated with imbalance between excess
production of reactive oxygen species (ROS) reflected by
increased serum indices of lipid peroxidation by mono-
cytes and polymorphonuclear leukocytes [2, 3], protein
products and a reduction in plasma antioxidants [5]. The
increased oxidative stress may partially result from acti-
vation of leukocytes interacting with the dialyzer artificial
membrane [3] and can cause oxidation of biologic macro-
molecules, including proteins and lipids [6, 7]. Among
these molecules, oxidized low-density lipoprotein (LDL)
can increase adhesion of monocytes to the endothelium
and transformation of macrophages into foam cells and
impair endothelium-dependent vasorelaxation [8–10].
These changes could lead to the development of athero-
sclerosis and coronary artery disease [9–11].
The two major ROS generated from activated neutro-
phils via the myeloperoxidase (MPO) system are hydro-
gen peroxide (H2O2) and hypochlorite (HOCl) [12]. The
primarily sensitive and specific product of lipid peroxi-
dation that can readily be measured in the laboratory is
phosphatidylcholine hydroperoxide (PCOOH) [13]. Two
other oxidized products, dityrosine and methylguanidine
(MG), were also widely used as indirect indicators for ROS
and/or free radical activities [14, 15].
Electrolyte reduced water (ERW) obtained by elec-
trolysis scavenges ROS and protects DNA from oxida-
tive damage [16]. The protective mechanism of ERW
results from active atomic hydrogen with high reducing
ability, which can contribute to ROS scavenging activity,
and may participate in the redox regulation of cellular
function [16]. Hemodialysis produces ROS in blood dur-
ing dialysis and imposes heavy burden on patients; there-
fore, for decreases of hemodialysis-enhanced oxidative
stress, we have considered administering ERW by a new
setup of HD-24K (Nihom Trim Co., Osaka, Japan) to
the patients during hemodialysis course. Three months
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of hemodialysis session were used in this study as in vivo
system to evaluate the effect of ERW on dialysis-induced
oxidative stress. We clarified the response of H2O2/HOCl
system and to identify which ROS is scavenged by hemo-
dialysis session with ERW administration. We used a
characteristic emission spectrum analysis of the chemilu-
minescence (CL) spectrum for the first time to evaluate
the specific ROS activity, including H2O2 and HOCl in the
plasma and adapted a CL high-performance liquid chro-
matography (CL-HPLC) for measurement of PCOOH
before and after the dialysis session, in the absence and
presence of ERW. Our study showed that ERW admin-
istration partially restored ROS scavenging activity for
H2O2 and HOCl. This treatment also resulted in lower
plasma levels of oxidized lipids and proteins, and inflam-
matory markers in ESRD patients as compared to those
before ERW treatment. Dialysate with simultaneous ERW
replacement might be of clinical importance for pre-
venting oxidative stress induced cardiovascular events
in ESRD patients undergoing chronic hemodialysis.
METHODS
Patients
Ten healthy volunteers (three women and seven men;
mean  SD; age 45  12 years; range, 38 to 60 years)
with cholesterol 189  11 mg/dL and creatinine 1.0 
0.1 mg/dL were enrolled in this study. To assess the
extent of oxidative stress in blood of ESRD patients, 37
patients (22 males and 15 females) with 10.3 0.6 mg/dL
of creatinine, subjected to maintenance hemodialysis at
Wan-Hwa Hospital for a period of 12  2 months, after
informed consent was obtained, were enrolled in this
study. Criteria for patient selection included the absence
of habit of smoking, malignancy, inflammatory disorders,
chronic or acute infections, supplementation of vita-
min C or E, and treatment either oral or intravenous iron,
or anti-inflammatory drugs 3 months before enrollment.
The mean age was 63  2 years old (mean  SEM,
range 46 to 81 years). All hemodialysis patients received
a standard bicarbonate dialysis schedule of 4 hours, three
times a week, using a single use of Hemodialyzer (AF-150
and AF-180 membrane type; Althane, Althin Medical,
Inc., Miami, FL, USA). The blood flow rate during the
dialysis sessions was 250 to 300 mL/min and dialysate
flow was 500 mL/min. The surface area of these two
dialyzers was 1.5 m2 and 1.8 m2 respectively, and patient
treatment with either membrane lasted for 6 months.
The Kt/V of all these patients was maintained between
1.3 and 1.6. The cause of ESRD was diabetes in 18
patients and chronic glomerulonephritis in 19 patients.
Hemodialysis patients were on a free diet with a normal
and constant intake of essential fatty acids, and none of
them took any drug with established or potential oxidiz-
ing effect or any antioxidants such as vitamin C or E
during the 3 months of the testing period. The permission
for a clinical trial was approved by the Human Research
Committee of the Wan-Hwa Regional Hospital.
Structure of HD-24K and electrolyzed reduced water
HD-24K (Nihom Trim Co.) was composed of an elec-
tric power supply unit for converting business purpose
power supply to direct current power supply, an indica-
tion/operation unit that indicated and controlled the op-
eration of the device, a control unit that input and output
the data between the whole bodies of the device, and a
personal computer with a remote control (Fig. 1). In
addition, the unit adopts the original constant current
system at the power supply unit to prevent the difference
of electrolysis current occurred by the difference of elec-
tronic conductivity of the supplied water.
Raw water was supplied from “in” after being com-
pressed by the compression pump and supplied into a
compartment for electrolysis through a solanoid valve,
which opened and closed synchronizing with the signal
of water level sensor in electrolyzed water storage tank,
flow sensor, and cross line “in” (watercourse exchanging
unit). At the electric compartment, the supplied raw
water was electrolyzed by direct current supplied to 
and  electrode plate (Type TI-7000S and TI-7000SL,
Nihon Trim Co.) across the diaphragm and then, at the
side of  electrode plate, reduced water containing ac-
tive hydrogen, and at the side of electrode, plate acidic
water, were collected from “out” and “drain” through
cross-line “out” (watercourse exchanging unit), respec-
tively. The series of operation were automatically done
according to the level of reduced water tank.
The example of the system in which HD-24K is applied
the hemodialysis system is indicated in Figure 1. HD-
24K, compression pump, reduced water tank, acidic wa-
ter tank, and personal computer for control were placed
in front of the usual raw water processing device. More-
over, for the HD-24K system, an unused pipe arrange-
ment and valve for bypass were installed. The reduced
water produced by HD-24K was collected in the reduced
water tank, and then was supplied to usual raw water
processing system for hemodialysis by compression with
the compressing pump.
The pH of electrolyzed-reduced water correspondence
to the level for adjusting the electrolysis intensity, which
showed in the example of a system in 5, is indicated as
follows (the water right after collecting from “out” of
HD-24K): level 1, pH  9.5; level 2, pH  9.8; level 3,
pH  10.0; and level 4, pH  10.1. The intensity of
electrolysis of HD-24K was adjusted to “level 2” and
the ERW that indicated pH 9.8 right after taking from
“out” of HD-24K was used in this study. The quality of
ERW for hemodialysis was approved by Yen Tjing Ling
Industrial Research Institute, National Taiwan Univer-
sity, with the No. E89A299D277, which is required by the
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Fig. 1. The system in which HD-24K is applied
to hemodialysis system is indicated. HD-24K,
compression pump, reduced water tank, acidic
water tank, and personal computer for control
are placed in front of usual raw water processing
device. The intensity of electrolysis of HD-24K
is adjusted to “level 2” and the electrolyzed
reduced water (ERW) that indicates pH 9.8
right after taking from “out” of HD-24K is
used in this study.
American Association of Medical Instruments (AAMI).
The endotoxin level in the water used for hemodialysis
is 0.069  0.004 EU/mL measured by an endotoxin en-
zyme-linked immunosorbent assay (ELISA) kit (HBT-
HIT301, Biocompare Inc., South San Francisco, CA, USA)
and an automated ELISA analyzer (CODA, SN10373,
Hercules, CA, USA).
Blood samples and biochemical analysis
Ten milliliters of blood were drawn from the arterial
side of the arteriovenous fistula before and after dialysis
in hemodialysis patients. Then blood was collected into
heparinized sterile test tubes and processed within
2 hours. Plasma was separated from blood cells by cen-
trifugation at 1500 g for 5 minutes at 4C. The plasma
was immediately stored at 70C and analyzed within
2 weeks.
Plasma total cholesterol, triglycerides, and high-den-
sity lipoprotein (HDL) levels were assessed enzymati-
cally by automated procedures. LDL, very low-density
lipoprotein (VLDL), and cholesterol values were mea-
sured as previously described [17]. The measurement of
lipoprotein(a) [Lp(a)] was performed with a commercial
LPA kit (Kit Recorder #465360, Beckman Coulter Array
System, Denmark). Quantitative determination of fi-
brinogen levels in plasma was made by FIBRI-PREST
AUTOMATE (Diagnostica Stago, Asnieres-Sur-Seine,
France).
Red and white blood cells, hemoglobin level, hemato-
crit level, and platelets were determined by an autoana-
lyzer (Coulter STKS, Hialeah, Finland). Plasma total
protein, albumin, urea nitrogen, creatinine, and alkaline
phosphatase levels were determined by an autoanalyzer
(Hitachi 736-15, Ibaraki, Japan).
Total antioxidant status (TAS) assay
The total antioxidant status (TAS) in 20 L of plasma,
ERW, or distilled water (as a blank) was measured with
a TAS kit (Cat. # NX2332, Randox, San Francisco, CA,
USA) according to the manufacturer’s instructions.
Briefly, 20L of sample was added to 1 mL of 6.1mol/L
metmyoglobin and 610 mol/L ABTS (2,2’-Azino-di-
3-ethylbenzthiazoline sulphonate). After thorough vor-
texing, the absorbance of the mixture was measured at
600 nm by an autoanalyzer (Tectron U-240 Plus, Japan).
6-Hydroxy-2,5,7,8-tetramethylchromon-2-carboxylic acid
was used a standard. The assay principle was that the
ABTS was incubated with a peroxidase and H2O2 to
produce the radical cation ABTS. It has a relatively
stable blue-green color, which was measured at 600 nm.
Antioxidants in the added sample caused suppression of
this color production to a degree, which was proportional
to their concentration.
Measurement of specific plasma antioxidant activity
CL signals emitted from the “test mixture” of plasma
[or phosphate-buffered saline (PBS) (50 mmol/L, pH
7.4) as a background control], H2O2 (or HOCl), and CL-
emitting substance [i.e., luminol (5-amino-2,3-dihydro-
1,4-phthalazinedione); Sigma,Chemical Co., St. Louis,
MO, USA] was measured with a multiwavelength CL
spectrum analyzer (CLA-SP2, Tohoku Electronic Ind.,
Co., Sendai, Japan).
We noted that the CL signals emitted from the H2O2-
luminol-plasma mixture (or HOCl-luminol-plasma mix-
ture) decreased as the volume of added plasma in the
test mixture rose (Fig. 2). In this study, we used 25 L
of plasma sample or 25 L of PBS throughout. We first
mixed 25 L of plasma and 1.0 mL of 25 mol/L luminol
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in a 4.0 mL quartz cell (1  1  4 cm) for 100 seconds.
Next, 1.0 mL of 0.03% H2O2 or 0.012% NaOCl was
immediately added into the quartz cells. Luminol stock
solution (250 mol/L) was prepared as 1 mg of luminol
dissolved in 22.7 mL of PBS.
The CL emitted from the above reaction mixture was
recorded and measured as “reference H2O2 counts”
(Rh2o2) or “reference HOCl counts” (Rhocl). Plasma
from healthy donors was used for measurement of nor-
mal Rh2o2 and Rhocl. PBS was added to the test system,
and the Rh2o2 and Rhocl yielded were recorded as the
background counts (i.e., total Rh2o2 and Rhocl without
inhibition by plasma). A higher Rh2o2 or Rhocl indicated
lower antioxidative activity and/or lower ROS scaveng-
ing ability.
Using the above system, we also tested antioxidant ac-
tivity of vitamin C (1 mg/mL), a scavenger for H2O2 [18],
and () epigallocatechin-3-gallate (EGCG) (1 mg/mL),
a scavenger for HOCl [19], ERW collected from extra-
corporeal system, PBS, and normal plasma on the re-
sponse of Rh2o2 or Rhocl.
Measurement of oxidized protein/amino acid products
In the presence of H2O2, the enzyme MPO can gener-
ate tyrosyl radicals by abstraction of H• from the OH
group on tyrosine, and the tyrosyl radicals may partici-
pate in the oxidation of LDL [20]. When a tyrosyl radical
is generated in biologic systems, it often cross links to
give a fluorescent adduct, dityrosine, which can be deter-
mined with a fluorometer (Hitachi F-2500, Tokyo, Ja-
pan), as described previously [15]. The sample (5 L of
serum in 1 mL of distilled water) was measured at an
excitation wavelength of 315 nm and an emission wave-
length of 410 nm.
The hydroxyl radical, an important product of ROS,
is known to play a role in the biosynthesis of MG, which
contributes to toxicity in uremic patients. The MG with
fluorescent activity, as an indirect measure of hydroxyl
radical activity, was determined as described previously
[16]. The sample was assayed at an excitation wavelength
of 395 nm and an emission wavelength of 500 nm. The
concentrations of dityrosine or MG were displayed as
fluorescence intensity/mL (FI/mL).
Measurement of lipid peroxidation products
For measurement of oxidation of LDL, the competi-
tion ELISA method is developed to detect malondialde-
hyde (MDA)-LDL and oxidized LDL in circulating
plasma using monoclonal antibodies 4E6 and 1H11 [21].
Both antibodies 4E6 and 1H11 react not only to oxidized
LDL but also to MDA-LDL. Because MDA is one of
those lipid peroxidation products that is highly sensitive
reactive to lysine residues, MDA-LDL has been widely
used as a way to detect and quantify oxidized LDL.
However, despite the fact that oxidized LDL contains
MDA-induced modifications of the apolipoprotein B
(apoB) protein, MDA-LDL cannot be considered identi-
cal to oxidized LDL [22]. Watson et al [23] demonstrated
that oxidized phosphatidylcholine (PC) separated from
minimally modified LDL, prepared by mild oxidation of
LDL, was capable of inducing monocyte adhesion to
endothelial cells and neutrophil migration. They suggest
that oxidized PC is one of the key molecules in oxidized
LDL and is directly involved in the early development of
atherosclerosis. Therefore, in this experiment, measuring
oxidized LDL in circulating plasma using PCOOH, a
primary lipid peroxidation products, could provide a
means to monitor the behavior of oxidized PC particles
as part of oxidized LDL in plasma LDL fractions.
The amounts of PCOOH were determined in dupli-
cate by CL-HPLC) (Tohoku Electronic Ind., Co.) [13].
Briefly, the total lipids were extracted from 0.5 mL of
plasma, with 2 mL of chloroform and methanol mixture
(2:1, vol/vol, containing 0.002% butylated hydroxytoluene
as an antioxidant) added, followed by vigorous mixing.
The extraction was repeated and the chloroform layer
collected. After dehydration and evaporation of the com-
bined chloroform layer, the dried total lipid residue was
diluted with 40 L of chloroform-methanol (2:1, vol/vol)
and a 20 L portion was used for CL-HPLC. CL was
produced through luminol oxidation during the reaction
between PCOOH and cytochrome c.
Interleukin-6 (IL-6) and C-reactive protein
(CRP) assay
In the present study, cytokine release [interleukin-6
(IL-6)] and subsequent production of acute phase pro-
teins [C-reactive protein (CRP)] were assessed to investi-
gate whether the ERW dialysate can ameliorate hemodi-
alysis-enhanced CRP and IL-6 levels. For in vitro use
with the IMMULITE Analyzer (Diagnostic Products
Corporation, Los Angles, CA, USA), the quantitative
measurement of IL-6 (LK6PZ) by sequential immuno-
metric assay in heparinized plasma was performed as an
aid in the study of inflammatory diseases. Samples were
analyzed in duplicate, according to the manufacturer’s
instructions. The lower limit of detection was 5 pg/mL.
Serum CRP concentrations measured by an immunome-
tric kit (717-80A3, Iatron Laboratories, Inc., Tokyo, Ja-
pan) were determined by an autoanalyzer (Tectron
U-240 Plus). The lower limit of detection of CRP was
0.3 mg/L.
Statistical analysis
All values are expressed as mean  SEM, and P 
0.05 was considered to indicate statistical significance.
The values were analyzed by t test and analysis of variance
(ANOVA) for repeated measures where appropriate.
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Fig. 2. Typical emission spectra of the chemi-
luminescence (CL) of a test mixture containing
H2O2 and luminol for reference H2O2 (RH2O2),
HOCl, and luminol for reference HOCl (RHOCl)
and different volumes of plasma or [phosphate-
buffered saline (PBS)] obtained from a healthy
control. Increased plasma volume (from 0 to
100 L) added to the test mixture could lower
both Rh2o2 and Rhocl counts. Mean change of
Rh2o2 and Rhocl counts with different plasma
volume added to the test mixture was displayed
in the right panels.
RESULTS
ERW exerted potent antioxidant activity for RH2O2
and RHOCl
Figure 2 shows a typical CL emission from H2O2
(counts/300 seconds) in the presence of a plasma sample
(or PBS), luminol, and 0.03% H2O2. The H2O2 CL has
a wide emission wavelength region of 370 to 650 nm with
an emission maximum of 460 nm. The CL count read at
emission maximum was expressed as Rh2o2. The back-
ground Rh2o2 in the PBS-luminol-0.03% H2O2 mixture
was 756 145 counts. When increased volume of plasma
from healthy individuals was added, the Rh2o2 decreased
to 198  32 counts, 95  18 counts, 64  14 counts,
and 35  3 counts (100 L, 50 L, 25 L, and 10 L,
respectively) indicating the presence of H2O2 scavenger
activity in plasma (Fig. 2).
The HOCl CL has a wide emission wavelength region
of 350 to 670 nm with an emission maximum of 520 nm
(Fig. 2). The Rhocl in the PBS-luminol-0.012% HOCl
mixture was 1124  16 counts. When different volume
of control plasma was added, the Rhocl was reduced to
576  59 counts, 101  19 counts, 71  10 counts, and
13  1 counts (100 L, 50 L, 25 L, and 10 L, respec-
tively) also indicating the presence of HOCl scavenger
activity in plasma (Fig. 2).
Ascorbate (1 mg/mL in 25 L), EGCG (1 mg/mL in
25L), ERW (25L), and normal plasma (25L) added
to the test mixture revealed strong H2O2 scavenger activ-
ity in an order EGCG  ascorbate 	 normal plasma 	
ERW 		 PBS, as shown by a reduction in Rh2o2
(Fig. 3A). Ascorbate, EGCG, normal plasma, and ERW
seem to be effective scavengers for Rh2o2. However,
ascorbate (1 mg/mL in 25 L), EGCG (1 mg/mL in
25L), ERW (25L), and normal plasma (25L) added
to the test mixture revealed HOCl scavenger activity in
an order EGCG 	 normal plasma 	 ERW 		 PBS 
ascorbate, as shown by a reduction in Rhocl (Fig. 3B).
EGCG, normal plasma, and ERW seem to be effective
scavengers for Rhocl, but not ascorbate. ERW displayed
antioxidant activities for both H2O2 and HOCl.
ERW reduced hemodialysis-enhanced RH2O2 and
RHOCl counts
In Figure 4, typical emission of Rh2o2 and Rhocl from
one ESRD patient was displayed before ERW treat-
ment, and during initial and 1-month ERW treatment.
We noted that prehemodialyis value of Rh2o2 and Rhocl
was similar in the group without ERW treatment and
ERW-treated group. Response of Rh2o2 and Rhocl in post-
hemodialysis plasma was significantly increased when
compared to respective prehemodialysis value of Rh2o2
and Rhocl. However, the enhanced response of Rh2o2
and Rhocl was partly decreased by ERW treatment.
As shown in Figure 5, the mean value of Rh2o2 and
Rhocl was 87  14 and 65  10 counts in nonhemodi-
alysis plasma from 10 healthy individuals. The prehemo-
dialysis value of Rh2o2 and Rhocl was 154 18 and 97
16 counts, respectively, in 37 ESRD patients’ plasma
without ERW treatment. This data directly indicate that
a significantly increased oxidative stress occurred in
ESRD patients. After single hemodialysis course without
ERW treatment, both Rh2o2 and Rhocl counts were
significantly increased to 416  46 and 210  17 counts
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Fig. 3. Typical emission spectra of the reference H2O2 (RH2O2) (A) and
reference HOCl (RHOCl) (B) counts with various kinds of antioxidants
[vitamin C, epigallocatechin-3-gallate (EGCG), and electrolyzed reduced
water (ERW)], plasma from healthy subjects and phosphate-buffered
saline (PBS) are displayed. Vitamin C, ERW, plasma, and EGCG sig-
nificantly reduced Rh2o2 counts, whereas ERW, plasma, and EGCG,
but not vitamin C, decreased Rhocl counts.
(P  0.05), respectively, when compared to their pre-
hemodialysis values (154  18 and 97  16 counts).
After initial and 1-month ERW treatment, the prehe-
modialysis values of Rh2o2 and Rhocl in the ESRD
plasma were not significantly affected when compared
to those in without ERW treatment (Rh2o2, 154  18
counts in the group without ERW treatment vs. 158 
23 counts in initial ERW treatment and 174  9 counts
in 1-month ERW treatment, respectively; Rhocl, 97 
16 counts vs. 92  23 counts in initial ERW treatment
and 87  21 counts in 1-month ERW treatment, respec-
tively). However, the posthemodialysis values in Rh2o2
and Rhocl were significantly reduced by ERW treatment
after initial (304  16 counts in Rh2o2 and 154  11
counts in Rhocl) and 1-month (262 31 counts in Rh2o2
and 134  7 counts in Rhocl) of ERW treatment (P 
0.05).
ERW partly restored TAS
The effect of reducing oxidative stress by ERW was
further confirmed by the mildly increased TAS in prehe-
modialysis plasma and partly restored in posthemodialy-
sis plasma after 1-month ERW treatment (Fig. 6B). The
plasma TAS was significantly higher in healthy controls
than in ESRD patients. Hemodialysis reduced the
plasma TAS, and the reduction could be partially re-
stored by 1-month ERW administration. More signifi-
cantly, ERW appeared markedly to enhance the scav-
enging activity for H2O2 and HOCl (Fig. 5).
Effects of ERW on biochemical parameters
A single session of hemodialysis with or without ERW
treatment similarly decreased body weight (from 63.1 
1.91 kg to 59.9  1.83 kg), blood urea nitrogen (from
70.8  5.4 mg/dL to 21  2.1 mg/dL), and creatinine
(from 12.3  0.6 mg/dL to 5.1  0.4 mg/dL), increased
white blood cell (from 5842 287 L to 6108 332 L),
increased hemoglobin (from 10.9  0.40 g/dL to 12.6 
0.50 g/dL), increased hematocrit (from 32.2  1.2% to
37.0  1.5%), and increased platelets (from 171  8 
103/L to 201  8  103/L) in 37 ESRD patients. The
prehemodialysis and posthemodialyis levels of LDL,
VLDL, and Lp(a) with or without ERW treatment are
displayed in Table 1.
The levels of lipid-peroxidation primary products
(PCOOH), and protein/amino acid oxidation products
(MG and dityrosine) in ESRD patients before and after
hemodialysis with and without ERW treatment are dis-
played in Figure 6.
In ESRD patients, the levels of PCOOH (192 
18 ng/mL), MG (529 48 FI/mL), and dityrosine (7404
359 FI/mL) were significantly higher than those in
healthy controls (PCOOH, 44  10 ng/mL; MG, 237 
41 FI/mL; and dityrosine, 1658 232 FI/mL) (P 0.05),
also indicating an increased oxidative stress status in
ESRD condition. After hemodialysis without ERW
treatment, the levels of PCOOH were increased signifi-
cantly (P  0.05) (from 192  18 ng/mL to 652 
76 ng/mL), but dityrosine decreased after hemodialysis
session (from 7404  359 FI/mL to 5118  313 FI/mL)
(P  0.05). MG was only marginally increased after
hemodialysis without ERW (from 529  48 FI/mL to
548 53 FI/mL). With initial and 1-month ERW admin-
istration, the posthemodialysis PCOOH levels were sig-
nificantly reduced (190 18 ng/mL and 335 47 ng/mL),
whereas the posthemodialysis levels of MG and di-
tyrosine were affected marginally. The mild reduction
in MG or dityrosine in posthemodialysis plasma was
found after 1-month ERW treatment. PCOOH levels
after 1-month ERW treatment are higher than single
treatment with ERW. This discrepancy may be due to
a dietary factor that increased the levels in triglyceride
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Fig. 4. Hemodialysis (HD) effect on emission spectra of the reference H2O2 (RH2O2) and reference HOCl (RHOCl) counts of prehemodialysis and
posthemodialysis plasma from one end-stage renal disease (ESRD) patient before electrolyzed reduced water (ERW) treatment (A), after initial
ERW (B), and 1-month ERW (C ) treatment are displayed. Before ERW treatment, the postdialysis plasma had significantly elevated Rh2o2 and
Rhocl counts when compared to each prehemodialysis value. Initial and 1-month ERW supplement resulted in augmented reactive oxygen species
(ROS) scavenging activity for both H2O2 and HOCl, as shown by the marked reduction of Rh2o2 and Rhocl counts in posthemodialysis plasma.
and VLDL in the ESRD patients with 1-month ERW
treatment (Table 1).
As shown in Table 1, the prehemodialysis level of
CRP and IL-6 was efficiently (P  0.05) reduced with
ERW treatment in 10 ESRD patients with detectable
CRP and IL-6 levels.
DISCUSSION
Hemodialysis efficiently removed blood urea nitrogen
and creatinine, but had no effects on atherogenic sub-
stances, such as total LDL, cholesterol, plasma Lp(a),
fibrinogen, and oxidized products from hemodialysis pa-
tients. Hemodialysis appears to cause an acute and tran-
sient reduction in endogenous antioxidant ability, as
shown by the decrease in TAS (our data) and increased
production of ROS by leukocytes after hemodialysis. As
a result, there was an increase in patients’ plasma Rh2o2
and Rhocl after hemodialysis. ERW administration dur-
ing hemodialysis session partly restored TAS and effi-
ciently diminished Rh2o2 and Rhocl. More significantly,
the level of oxidative products of lipid and protein can
be partly reduced by ERW supplement, despite the oxi-
dative stress accompanying hemodialysis.
The increased ROS found in patients with ESRD under-
going chronic hemodialysis could originate from comple-
ment-, platelet-, and even dialysis membrane–activated leu-
kocytes [24, 25]. The self-perpetuating formation of H2O2
and HOCl from leukocytes may potentially oxidize protein
and LDL, change the lipid composition of cell membranes
and the extracellular matrix [26, 27], and consequently
lead to atherogenic injury. Cells (such as endothelial
cells) are more prone to oxidative damage when exposed
to H2O2 as compared to HOCl [28]. However, when
combined with H2O2, HOCl increased H2O2-mediated
oxidative damage and compromised the repair process.
Increased plasma H2O2 by reducing the bioavailability
of nitric oxide (NO) and impairing normal platelet inhib-
itory mechanisms may cause thrombotic disorder in hu-
mans [29]. Other data also implicate that cardiopulmo-
nary bypass activates complement via the alternate (C3a)
pathway and increases plasma H2O2 by pulmonary se-
questration of polymorphonuclear leukocytes [30]. Acti-
vated phagocyte cells generate hypochlorite (HOCl) via
the release of H2O2 and the enzyme MPO. Plasma pro-
teins are major targets for HOCl. The reaction of fresh
diluted plasma with HOCl gives rise to protein-derived
nitrogen-centered radicals in a time- and HOCl concen-
tration–dependent manner; these have been detected by
electron paramagnetic resonance (EPR) spin trapping.
Identical radicals have been detected with isolated HOCl-
treated plasma proteins [31]. Thus, antioxidant treatment
that can reduce HD-induced H2O2 and HOCl should be
beneficial for minimizing oxidative damage to leukocytes
and endothelial cells.
Based upon the interesting clinical improvement of a
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Fig. 5. Effects of hemodialysis (HD) and electrolyzed reduced water
(ERW) supplement on reference H2O2 (RH2O2) (A), and reference
HOCl (RHOCl) (B) counts in plasma obtained from 37 end-stage renal
disease (ESRD) patients. The levels of Rh2o2 and Rhocl of prehemodial-
ysis plasma in 37 ESRD patients were higher than those in 10 healthy
control subjects. The posthemodialysis plasma had elevated Rh2o2 and
Rhocl, However, after initial (AIERW) and 1-month ERW (A1M-
ERW) supplementation resulted in augmented reactive oxygen species
(ROS) scavenging activity for both H2O2 and HOCl, as shown by the
marked reduction of Rh2o2 and Rhocl. *P  0.05 the prehemodialysis
values of ERSD plasma vs. the values of healthy control plasma; #P 
0.05 the posthemodialysis values vs. the prehemodialysis value of the
respective group. aP  0.05 when compared to the value of ESRD
plasma without ERW (XERW) administration.
variety of diseases by intake of reduced water since 1985,
Hayashi [32] proposed the hypothesis “water regulating
theory.” The ideal scavenger for ROS should be “active
atomic hydrogen.” “Active atomic hydrogen” can be pro-
duced in reduced water near the cathode during electrolysis
of water. Reduced water exhibits high pH, low dissolved
oxygen, extremely high dissolved molecular hydrogen,
and extremely negative redox potential values [16]. Shir-
ahata et al [16] suggest that the superoxide dismutase
(SOD)- and catalase-like activity of ERW is not due to
the dissolved molecular hydrogen but due to the active
atomic hydrogen with a higher reducing ability that may
participate in ROS scavenging activity. Happe et al [33]
indicate that hydrogenases, which are among in the old-
est enzymes (3.8 billion years old), can reversibly split
molecular hydrogen to produce active atomic hydrogen,
which participates in the redox regulation of cellular
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Fig. 6. Effects of hemodialysis (HD) and elec-
trolyzed reduced water (ERW) supplement on
PCOOH (A), total antioxidant status (TAS)
(B), methylguanidine (MG) (C ), and dityro-
sine (DT) (D) in plasma obtained from 37 end-
stage renal disease (ESRD) patients. The levels
in PCOOH, MG, and DT of prehemodialysis
plasma in 37 ESRD patients without ERW
treatment (XERW) were higher than those in
10 healthy control subjects. A significant de-
crease in TAS of prehemodialysis plasma of was
found in ESRD patients. When compared to
prehemodialysis value, the posthemodialysis
plasma had significantly elevated PCOOH
levels and marginally increased MG and de-
creased TAS and DT values. Initial ERW
(AIERW) supplementation significantly re-
duced PCOOH levels, but did not significantly
affect TAS, MG, and DT values. However,
1-month ERW (A1MERW) supplementation
mildly restored TAS ability in posthemodialy-
sis plasma and consequently mildly reduced
PCOOH, MG, and DT levels in posthemo-
dialysis plasma. The level of PCOOH in post-
hemodialysis plasma after 1-month ERW treat-
ment was higher than that after initial ERW
treatment possibly by a dietary factor. Note that
a marginally increased TAS, and a decreased
MG was found in prehemodialysi plasma after
1-month ERW treatment. *P  0.05 the pre-
hemodialysis values of ERSD plasma vs. the
values of healthy control plasma. #P  0.05
the posthemodialysis values vs. the prehemo-
dialysis value of the respective group. aP 0.05
when compared to the value of ESRD plasma
without ERW (XERW) administration.
function. The ROS scavenging activity of ERW is stable
at 4C for over a month and was not lost even after
neutralization, repeated freezing and melting, deflation
with sonication, vigorous mixing, boiling, repeated fil-
tration, or closed autoclaving, but was lost by opened
autoclaving or by closed autoclaving in the presence of
tungsten trioxide, which efficiently adsorbs active atomic
hydrogen [16]. Strong ERW, as well as ascorbic acid
and catechin, completely scavenged superoxide anion
produced by the hypoxanthine-xanthine oxidase system
in sodium phosphate buffer [16]. Furthermore, ERW, as
well as catalase and ascorbic acid, could directly scavenge
H2O2 and possible 1O2 and ·OH [16]. In our experiment
with CL spectrum, we found that ERW and EGCG can
scavenge both H2O2 and HOCl, but ascorbic acid only
availably removes H2O2. The scavenging ROS mecha-
nism by ERW may be due to the direct adsorption of
ROS by active atomic hydrogen, because no antioxidant
production by TAS assay was detected in our experiment
(data unpresented). This result indicates that ERW with
a higher reducing ability and/or direct ROS scavenging
activity could be used in hemodialysis patients by its
stable characteristics, cheaper expense, and strong anti-
oxidant activity.
Hemodialysis does not efficiently and mechanically
remove atherogenic substances, such as total LDL, plasma
Lp(a), cholesterol, fibrinogen, and oxidized products
(PCOOH and MG) from ESRD patients. Furthermore,
hemodialysis-induced oxidative stress may, at the same
time, cause the production of oxidized lipid and protein
products. Among these products, PCOOH, accumulated
as a primary peroxidation product from membrane phos-
pholipids, was found to be a more sensitive marker than
MDA in reflecting lipid peroxidation [34]. Despite the
fact that oxidized LDL contains MDA-induced modifi-
cations of the apoB protein, MDA-LDL cannot be con-
sidered identical to oxidized LDL [22]. Watson et al
[23] also demonstrated that oxidized PC was capable
of inducing monocyte adhesion to endothelial cells and
neutrophil migration. They suggest that oxidized PC is
one of the key molecules in oxidized LDL and is directly
involved in the early development of atherosclerosis.
PCOOH is mostly distributed in the VLDL and LDL
fractions [9]. There was an increased fraction of VLDL
and LDL and a significant enhancement in the PCOOH
fraction after hemodialysis in ESRD patients without
ERW treatment. ERW with antioxidant activity may
reduce hemodialysis-induced oxidative stress and conse-
quently decrease the PCOOH level in ESRD patients.
The dialysis clearance of MG was found to be lower
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during a hemodialysis course. Its protein binding, which
rises as the plasma pH rises during hemodialysis, ac-
counts for its dialysis behavior. The low dialysis clearance
of MG explains why the postdialysis percentage decrease
in its plasma levels is lower than that of urea and of
creatinine [35]. The dialytic behavior of MG is different
from that of urea and of creatinine, which have similar
molecular weights and the conclusions drawn from the
behavior of the latter two metabolites cannot be applied
to MG. The slow transfer of MG from tissue during di-
alysis, shown by direct measurements on plasma of ESRD
patients, accounts for its high plasma rebound level after
hemodialysis. The increased PCOOH and MG level might
reflect increased ROS production under pathologic con-
ditions and even during hemodialysis courses. Simultane-
ous treatment with ERW effectively lowered the levels
of PCOOH as well as those of other oxidized products.
In chronic hemodialysis, morbidity may result from re-
petitive induction of the acute phase response and chronic
inflammation and cause by a bioincompatible dialysis
membrane [36] and/or contaminated dialysate [37]. Cy-
tokines released from jeopardized tissues stimulate the
liver to synthesize acute phase proteins, including CRP.
It has been suggested that CRP is useful not only as a
marker of the acute phase response, but is also involved
in the pathogenesis of the disease. CRP may directly inter-
act with the atherosclerotic vessels or ischemic myocar-
dium by activation of the complement system, thereby
promoting inflammation and thrombosis. Several studies
in uremic patients have implicated CRP as a marker of
malnutrition, resistance to erythropoietin, and chronic
stimulation in hemodialysis. An increased cytokine pro-
duction secondary to blood interaction with bioincom-
patible dialysis components has been reported by several
studies; interleukin-1, tumor necrosis factor-alpha, and
mainly IL-6 are the three proinflammatory cytokines in-
volved in the pathogenesis of hemodialysis-related dis-
ease. Panichi et al [37] have provided evidence for the
occurrence of high CRP and IL-6 levels in chronic hemo-
dialysis patients. Therefore, CRP is implicated as a marker
linking bioincompatibility and increased cytokine IL-6
production with a clinical state of chronic inflammation
[37]. The effects of initial ERW on most oxidative param-
eters (H2O2, HOCl, and PCOOH) at posthemodialysis
plasma are significant, but these effects cannot be seen
at prehemodialysis plasma. The decrease in several oxi-
dative parameters in ESRD patients by ERW replace-
ment may functionally restore TAS, which can reflect
the total effects on all parameters. Therefore, 1-month
ERW treatment mildly increased TAS and efficiently
reduced PCOOH, MG, and chronic inflammatory mark-
ers (CRP and LL-6) in the prehemodialysis plasma of
ESRD patients, expecting that a long-term outcome of
therapeutic potential by ERW treatment may gradually
improve constitutionally ESRD patients.
CONCLUSION
We have shown that hemodialysis with ERW supple-
ment might be of clinical importance for reduction in
oxidized macromolecules in ESRD patients with chronic
hemodialysis. ERW treatment and other measures that
can reduce ROS, particularly H2O2 and HOCl, should be
beneficial for minimizing oxidative damage to leukocytes
and endothelial cells. The application of ERW in dialy-
sate may efficiently ameliorate hemodialysis-enhanced
oxidative stress.
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